Skip to content

Evaluation of Bupropion Efficacy on Sexual Dysfunction among Male Patients on Methadone Maintenance Therapy

Evaluation of Bupropion Efficacy on Sexual Dysfunction among Male Patients on Methadone Maintenance Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014032616823N1
Enrollment
60
Registered
2014-03-26
Start date
2009-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual dysfunction. Lack or loss of sexual desire

Interventions

Intervention 1: intervention group- bupropion tab.100 mg Po for 3 days, then twice daily( 200mg/day) for 8 weeks. Intervention 2: control group: Placebo tab.100 mg po for 3 days, then twice daily( 200
Treatment - Drugs
intervention group- bupropion tab.100 mg Po for 3 days, then twice daily( 200mg/day) for 8 weeks.
control group: Placebo tab.100 mg po for 3 days, then twice daily( 200mg/day) for 8 weeks.

Sponsors

Isfahan University of Medical Sciences-Behavioral Sciences Research Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: Male gender;Having the minimum level of education in reading and writing; passing at least 6 months from the Methadone maintenance Therapy( MMT); Having complaints from the cause or aggravate of sexual dysfunction after methadone treatment; Lack of underlying diseases as epilepsy, diabetes, organic brain disease, and psychosis;Not receiving drugs affecting sexual function, such as SSRI, sildenafil, testosterone, antipsychotics, cyclic antidepressants, MAO-I, the lithium, amphetamines, chlordiazepoxide, clonidine, methyldopa, spironolactone hydrochlorothiazide, barbiturates, anti-Parkinson's drugs , clofibrate, digoxin, indomethacin, propranolol and phentolamine; No risk of major depressive disorder and a score of less than 16 based on the BDI-II, Having a total score of 19 or more based on the Arizona Sexual Experience Scale (ASEX) or a score of 5 or more on one of the items of ASEX or a score of 4 or more in any of 3 items; No alcohol consumption, recent cessation of benzodiazepines, and not using drugs or stimulants. Exclusion criteria: Leaving the MMT program; the decision of the therapist to stop the treatment with methadone or bupropion for any reason, and seizures.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sexual function. Timepoint: preintervention, post intervention at the end of 2, 4, 6,and 8 weeks. Method of measurement: Arizona sexual experiences scale(ASEX).

Secondary

MeasureTime frame
Depression total score. Timepoint: preintervention, post intervention at the end of 2,4,6 and 8 weeks. Method of measurement: Beck depression scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Salehi

Behavioral Sciences Research Center- Isfahan University of Medical Sciences

me_salehi@med.mui.ac.ir+98 31 1222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026